A1 beta-casein in conventional milk releases beta-casomorphin-7, which triggers gut inflammation, slower transit and worse symptoms (shown in a 2016 randomised trial).

Original statement

يُضاف لذلك بروتين بيتا-كازين A1 في الحليب التقليدي، الذي أثبتت تجربة Nutrition Journal عام 2016 أنه يُنتج ببتيد بيتا-كازومورفين-7 المسبّب لالتهاب الأمعاء وبطء الحركة الهضمية.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

A1 beta-casein in conventional milk releases beta-casomorphin-7, which triggers gut inflammation, slower transit and worse symptoms (shown in a 2016 randomised trial).

Origin

Source status

Archive editors

Attribution

Archive editors (eltayebat.com, rule 'dairy')

Origin

https://eltayebat.com/rule/dairy/

Attribution uncertainty

Editorial narrative and study selection by the archive operators, not shown to be Elawady's own words; the archive homepage says the forbidden section is documented 'independently of Dr. Diaa's words'.

Claimed mechanism

Opioid peptide beta-casomorphin-7 from A1 beta-casein digestion.

Claimed health effect

Gut inflammation, delayed transit, digestive discomfort, slower cognition.

Population concerned

People with self-reported milk intolerance (trial population); archive generalises.

Geographic restriction by Elawady

none found

Scientific assessment

Potentially true – Some evidence points in favour of the statement, but it is not sufficient for a clear judgement.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

A1 beta-casein causes gut inflammation and slow transit via BCM-7.

2. What is demonstrably correct?

A-DRY-10 found more digestive symptoms (bloating, flatulence), longer colonic (+6.6 h) and whole-gut (+6.3 h) transit and higher IL-4, IgE and IgG with A1+A2 milk vs A2-only milk; small-bowel inflammation on capsule images improved more often after switching to A2 milk (36.4% vs 11.1%). An independent systematic review (I-DRY-04, GRADE) concluded 'moderate certainty for adverse digestive health effects of A1 beta-casein compared with A2'.

3. What is wrong or exaggerated?

A-DRY-10 was designed and funded by The a2 Milk Company and one author was a company employee; 2-week periods; 45 participants with self-reported intolerance; no adjustment for multiple testing. Beta-casomorphin-7 concentrations are claimed in the abstract but are not reported in the main-text results, and two other pre-specified markers (GSH, MPO) are also missing; hs-CRP did not differ significantly (P=0.0608). The statement that the trial 'showed' BCM-7-triggered inflammation is therefore not verifiable, and RoB 2 is high (selective reporting). 'Proved' is too strong. The comparison is A1 vs A2 milk, not milk vs no milk: the finding would support A2 milk, not elimination of dairy. Cheese is made mainly from casein (including beta-casein) and the A1 argument would therefore apply to aged and processed cheeses allowed by the system as well (general dairy-science knowledge; Brooke-Taylor's review excluded cheese studies, so direct data are lacking).

4. What remains unclear?

Whether BCM-7 effects in fermented/aged cheese differ; effects beyond symptoms.

5. Which studies support it?

A-DRY-10 (symptoms and transit; BCM-7 data not reported; high risk of bias); I-DRY-04 (digestive symptoms, moderate certainty); I-DRY-05 (industry-linked review: delayed transit in 1 human study, looser stools in 2).

6. Which studies contradict it?

I-DRY-04: most RCTs on intermediate markers found no difference; other health outcomes low/very low certainty.

7. What applies to Germany and Europe?

EFSA reviewed beta-casomorphins in 2009 (report could not be accessed for this review; not used).

8. What is known about Egypt?

Egyptian cow and buffalo milk A1/A2 composition not examined here.

9. What practical conclusion is appropriate?

Some people may tolerate A2 milk better; this does not justify banning fresh milk while allowing casein-rich cheese.

Assessment details

Rationale for certainty of evidence

An independent systematic review rates the evidence for adverse digestive effects of A1 vs A2 as moderate; most human trials are small, short, and largely funded by the A2 milk industry; evidence for inflammation and other outcomes is low/very low. The archive's key trial (A-DRY-10) does not report the beta-casomorphin-7 results claimed in its abstract and is at high risk of bias for selective reporting, so the BCM-7 step of the claim is not verifiable.

Source quality

Archive editorial; 'proved' (أثبتت) overstates a single 45-person, industry-funded crossover trial.

Regional transferability

Trial in Han Chinese adults with self-reported lactose intolerance; transfer to other populations uncertain.

Individual exceptions

People who tolerate milk poorly may test A2 milk; this is an individual intolerance issue.

Regional scope of the claim

general (biological/medical)

Last reviewed

25 October 2026 provisional

In plain language

Cow's milk contains two forms of a protein called beta-casein, A1 and A2. A small trial in China found that people who felt milk did not agree with them had more stomach symptoms with ordinary milk than with A2-only milk. An independent review found moderate evidence for such digestive effects, but the trials are small and mostly paid for by an A2 milk company. The finding is about one milk type versus another, not about milk being harmful in general, and cheese contains the same proteins.

Studies on this claim

Regional context

Germany / EU

EFSA reviewed beta-casomorphins in 2009 (report could not be accessed for this review; not used).

Egypt

Egyptian cow and buffalo milk A1/A2 composition not examined here.

• Antimicrobial use in food animals and antibiotic growth promoters
• Hormones in poultry, meat, milk and farmed fish
• Dioxins, PCBs and PFAS in eggs and other animal foods
• Aflatoxin M1 in milk and dairy products
• Import controls and the meaning of RASFF notifications for Egyptian products

What applies in my country?

General scientific assessment

Potentially true A1 beta-casein may cause more digestive discomfort than A2 in some people, but the evidence is limited, industry-linked, and does not support the system's split between milk and cheese.

The following areas of food safety are relevant to this statement:

• Veterinary medicines and antibiotics
• Hormonal growth promoters
• Contaminants (heavy metals, PFAS, PCBs, dioxins, nitrate)
• Mycotoxins (mould toxins)
• Controls, imports, recalls, labelling

Dairy

Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.

Country of residence or purchase Compare with another country

References

1. Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows' milk.. Jianqin S et al.. Nutr J 2016 · PMID 27039383 · DOI 10.1186/s12937-016-0147-z
2. Systematic Review of the Gastrointestinal Effects of A1 Compared with A2 β-Casein.. Brooke-Taylor S et al.. Adv Nutr 2017 · PMID 28916574 · DOI 10.3945/an.116.013953
3. Milk A1 β-casein and health-related outcomes in humans: a systematic review.. Küllenberg de Gaudry D et al.. Nutr Rev 2019 · PMID 30722004 · DOI 10.1093/nutrit/nuy063